No items found.

Ozempic vs. Contrave

Published on 
February 3, 2025
Virta Team

Ozempic and Contrave differ in purpose and effectiveness. Ozempic is a GLP-1 agonist for type 2 diabetes and cardiovascular risk reduction, while Contrave, a combination of naltrexone and bupropion, focuses on chronic weight management. Ozempic delivers HbA1c reductions and moderate weight loss, while Contrave’s weight loss is less pronounced. Side effects differ: Ozempic causes nausea, while Contrave may lead to insomnia and mood changes. Ozempic costs $875/month, substantially higher than Contrave’s $300/month. Neither drug currently faces shortages.

How Ozempic Works

Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.

Common Side Effects

Nausea, vomiting, diarrhea, constipation, and abdominal pain.

Serious Potential Side Effects

Pancreatitis, gallbladder issues, kidney problems, and increased heart rate, thyroid cancer, anaphylaxis (or serious allergic reactions)

How Contrave Works

Bupropion enhances dopamine and norepinephrine activity, reducing appetite and cravings; Naltrexone modulates the brain’s reward system, reducing cravings and emotional eating behaviors by blocking opioid receptors.

Common Side Effects

Nausea, constipation, headache, dizziness, dry mouth, and insomnia.

Serious Potential Side Effects

Increased blood pressure, seizures (rare), suicidal thoughts, and liver damage.

Brand Name

Ozempic
Contrave

Generic Name

semaglutide
Bupropion/Naltrexone

Overview

Primarily prescribed for type 2 diabetes to improve blood sugar control. Also used for cardiovascular event risk reduction in patients with type 2 diabetes and established cardiovascular disease. Off-label use for weight management due to its appetite-suppressing effects.
Combines bupropion (an antidepressant) and naltrexone (an opioid antagonist) to target brain pathways involved in hunger and cravings, supporting weight management when paired with lifestyle changes.

Year Approved

2017 for weight management 2020 for cardiovascular risk reduction
2014

Category

GLP-1
Other

Indicated for

Type 2 diabetes management; reducing risk of major cardiovascular events in adults with type 2 diabetes and cardiovascular disease
Chronic weight management in adults with obesity or overweight with related conditions

Administration type

Injectable
Oral

Also used (but not approved) for

Weight Management

Frequency

Once / week
2x / day

Typical dose range

0.25–2.0 mg
8 / 90 mg–32 / 360 mg

Average cost per month

$875
$150-$300

Availability

No current shortages
No current shortages